Literature DB >> 21382131

Prognostic value of dual-time-point 18F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis.

Yukihiro Umeda1, Yoshiki Demura, Miwa Morikawa, Shingo Ameshima, Tatsuro Tsuchida, Yasuhisa Fujibayashi, Hidehiko Okazawa, Takeshi Ishizaki.   

Abstract

BACKGROUND AND
OBJECTIVE: The value of dual-time- point (18) F-FDG PET was investigated to predict the prognosis of patients with pulmonary sarcoidosis.
METHODS: Twenty-one patients with pulmonary sarcoidosis underwent (18) F-FDG PET examinations at two time points: an early scan at 60min and a delayed scan at 180min after injection of (18) F-FDG. Standardized uptake values (SUVs) at the two time points and the retention index (RI-SUV) calculated from these were evaluated. To evaluate disease progression, all patients underwent chest CT 1year after (18) F-FDG PET. Using these results, the accuracy of (18) F-FDG PET parameters and (67) Ga uptake for predicting disease persistence were compared, and the correlations between those parameters and serum markers were assessed.
RESULTS: RI-SUV was significantly higher in patients with increased or unchanged pulmonary lesions at follow-up CT (persistent group; 21.3±9.6%) than in patients with improved pulmonary lesions (improved group; -9.2±28.6%, P=0.0075). The diagnostic accuracy of RI-SUV in the persistent group was significantly greater than that of early SUV or (67) Ga uptake, and serum soluble IL-2 receptor showed a significant correlation with RI-SUV.
CONCLUSIONS: RI-SUV showed better diagnostic accuracy compared with early SUV or (67) Ga uptake, in patients with persistent lung involvement at 1year. It may be a useful measure of persistent inflammation in patients with pulmonary sarcoidosis.
© 2011 The Authors; Respirology © 2011 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21382131     DOI: 10.1111/j.1440-1843.2011.01966.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  8 in total

1.  Year in review 2011: respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging.

Authors:  José M Porcel; Chi Chiu Leung; Marcos I Restrepo; Pyng Lee
Journal:  Respirology       Date:  2012-04       Impact factor: 6.424

2.  Relationship Between Dual-Time Point FDG PET and Immunohistochemical Parameters in Preoperative Colorectal Cancer: Preliminary Study.

Authors:  Jai Hyuen Lee; Won Ae Lee; Seok Gun Park; Dong Kook Park; Hwan Namgung
Journal:  Nucl Med Mol Imaging       Date:  2012-01-03

3.  The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis.

Authors:  Pei-Ing Lee; Gang Cheng; Abass Alavi
Journal:  J Nucl Cardiol       Date:  2016-11-03       Impact factor: 5.952

Review 4.  When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?

Authors:  Gang Cheng; Drew A Torigian; Hongming Zhuang; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01-30       Impact factor: 9.236

Review 5.  Assessment of cardiac sarcoidosis with advanced imaging modalities.

Authors:  Makoto Orii; Toshio Imanishi; Takashi Akasaka
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

6.  Imaging observations of pulmonary inflammatory myofibroblastic tumors in patients over 40 years old.

Authors:  Jiang Wu; Hong Zhu; Kai Li; Cai-Yun Yuan; Yan-Fen Wang; Guang-Ming Lu
Journal:  Oncol Lett       Date:  2015-02-02       Impact factor: 2.967

7.  Semi-quantitative metabolic values on FDG PET/CT including extracardiac sites of disease as a predictor of treatment course in patients with cardiac sarcoidosis.

Authors:  Mitsutomi Ishiyama; Laurie A Soine; Hubert J Vesselle
Journal:  EJNMMI Res       Date:  2017-08-18       Impact factor: 3.138

8.  Predictive value of integrated 18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer.

Authors:  Yukihiro Umeda; Miwa Morikawa; Masaki Anzai; Shingo Ameshima; Maiko Kadowaki; Yuko Waseda; Hiroko Shigemi; Tetsuya Tsujikawa; Yasushi Kiyono; Hidehiko Okazawa; Tamotsu Ishizuka
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.